



October 23, 2025

Company name: PeptiDream Inc.
Representative: Patrick C. Reid, President and CEO
(Securities code: 4587; TSE Prime Market)
Inquiries: Yuko Okimoto, Head of Investor Relations
(Tel: +81-44-223-6612)

(Correction) Regarding the Cause Analysis and Implementation of Recurrence Prevention Measures Based on the Findings of the Special Investigation Committee

KANAGAWA, JAPAN –October 23, 2025 - PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream") (Tokyo: 4587) today announced that the following partial corrections to the notice titled "Regarding the Cause Analysis and Implementation of Recurrence Prevention Measures Based on the Findings of the Special Investigation Committee" on October 23, 2025. The underlined portions indicate the corrections.

1. Reason for the Correction

Following the release of the document titled "Regarding the Cause Analysis and Implementation of Recurrence Prevention Measures Based on the Findings of the Special Investigation Committee", it was discovered that part of the content in the Japanese version contained an error. We hereby issue a correction.

2. Details of the Correction

The corrected portion (Japanese version only) is indicated with an underline.

【Before Correction】

5. Other Actions

- Two Executive Vice President and Director:

Voluntary 10% reduction of one month's compensation

【After Correction】

5. Other Actions

- **Executive Vice President and Director:**

Voluntary 10% reduction of one month's compensation